Aus HL7 Austria MediaWiki
Hauptseite > 1.2.40.0.34.10.54/static-2013-09-12T000000
Id | 1.2.40.0.34.10.54 | Gültigkeit | 2013‑09‑12 |
---|
Status | Veraltet | Versions-Label | |
---|
Name | ELGA_LaborparameterErgaenzung | Bezeichnung | ELGA_LaborparameterErgaenzung |
---|
Quell-Codesystem | |
---|
Level/ Typ | Code | Bezeichnung | Codesystem |
---|
0‑S | 1 | Allgemeiner Laborbefund | 1.2.40.0.34.5.11 | 1‑L | 10 | Probeninformation | 1.2.40.0.34.5.11 | 1‑L | 20 | Befundbewertung | 1.2.40.0.34.5.11 | 1‑S | 100 | Blutgruppenserologie/Immungenetik | 1.2.40.0.34.5.11 | 2‑L | 101 | Blutgruppenserologie | 1.2.40.0.34.5.11 | 2‑L | 102 | HLA-Diagnostik | 1.2.40.0.34.5.11 | 2‑L | 103 | HPA-Diagnostik | 1.2.40.0.34.5.11 | 1‑S | 200 | Blutgasanalyse | 1.2.40.0.34.5.11 | 2‑S | 201 | Blutgasanalyse Arteriell | 1.2.40.0.34.5.11 | 2‑S | 202 | Blutgasanalyse Venös | 1.2.40.0.34.5.11 | 2‑L | 203 | Blutgasanalyse Nabelschnurblut | 1.2.40.0.34.5.11 | 1‑S | 300 | Hämatologie | 1.2.40.0.34.5.11 | 2‑S | 301 | Blutbild | 1.2.40.0.34.5.11 | 3‑L | AKLAM | Akt.Lymphoz.abs.mi. | 1.2.40.0.34.5.11 | 3‑L | AKLRM | Akt.Lymphoz.rel.mi. | 1.2.40.0.34.5.11 | 2‑S | 302 | Knochenmark Morphologie | 1.2.40.0.34.5.11 | 2‑S | 303 | Immunphänotypisierung | 1.2.40.0.34.5.11 | 3‑L | FZA10AK | FZA10AK | 1.2.40.0.34.5.11 | 3‑L | FZA4R | FZA4R | 1.2.40.0.34.5.11 | 3‑L | FZA510AK | FZA510AK | 1.2.40.0.34.5.11 | 3‑L | FZA5AK | FZA5AK | 1.2.40.0.34.5.11 | 3‑L | FZAKLEU | FZAKLEU | 1.2.40.0.34.5.11 | 3‑L | FZALZP | FZALZP | 1.2.40.0.34.5.11 | 3‑L | FZBAL | FZBAL | 1.2.40.0.34.5.11 | 3‑L | FZDNA | FZDNA | 1.2.40.0.34.5.11 | 3‑L | FZIMSTA | FZIMSTA | 1.2.40.0.34.5.11 | 3‑L | FZLK | FZLK | 1.2.40.0.34.5.11 | 3‑L | FZLYPA | FZLYPA | 1.2.40.0.34.5.11 | 3‑L | FZMYVD | FZMYVD | 1.2.40.0.34.5.11 | 3‑L | FZMYVL | FZMYVL | 1.2.40.0.34.5.11 | 3‑L | FZZAP70 | FZZAP70 | 1.2.40.0.34.5.11 | 2‑S | 304 | Molekulare Diagnostik | 1.2.40.0.34.5.11 | 1‑S | 400 | Hämostaseologie | 1.2.40.0.34.5.11 | 2‑S | 401 | Hämostaseologie Globaltests | 1.2.40.0.34.5.11 | 3‑L | CFTIN | Clot Form.Time INTEM | 1.2.40.0.34.5.11 | 3‑L | CFTEX | Clot Form.Time EXTEM | 1.2.40.0.34.5.11 | 3‑L | CFTNA | Clot Form.Time NATEM | 1.2.40.0.34.5.11 | 3‑L | CTAPT | Clotting Time APTEM | 1.2.40.0.34.5.11 | 3‑L | CTEXT | Clotting Time EXTEM | 1.2.40.0.34.5.11 | 3‑L | CTHEP | Clotting Time HEPTEM | 1.2.40.0.34.5.11 | 3‑L | CTINT | Clotting Time INTEM | 1.2.40.0.34.5.11 | 3‑L | CTNAT | Clotting Time NATEM | 1.2.40.0.34.5.11 | 3‑L | MCFEX | Max.Clot Firmn.EXTEM | 1.2.40.0.34.5.11 | 3‑L | MCFFI | Max.Clot Firmn.FIBT. | 1.2.40.0.34.5.11 | 3‑L | MCFIN | Max.Clot Firmn.INTEM | 1.2.40.0.34.5.11 | 3‑L | MCFNA | Max.Clot Firmn.NATEM | 1.2.40.0.34.5.11 | 3‑L | MLEXT | Maximal Lyse EXTEM | 1.2.40.0.34.5.11 | 3‑L | MLINT | Maximal Lyse INTEM | 1.2.40.0.34.5.11 | 3‑L | MLNAT | Maximal Lyse NATEM | 1.2.40.0.34.5.11 | 3‑L | NRMTC | Normotest /KB | 1.2.40.0.34.5.11 | 3‑L | THRTC | Thrombotest /KB | 1.2.40.0.34.5.11 | 3‑L | NORMT | Normotest | 1.2.40.0.34.5.11 | 3‑L | THROT | Thrombotest | 1.2.40.0.34.5.11 | 3‑L | INRTT | INRTT | 1.2.40.0.34.5.11 | 3‑L | INRST | INRST | 1.2.40.0.34.5.11 | 3‑L | APTTF | aPTT Fakt.-sens. | 1.2.40.0.34.5.11 | 3‑L | PFAINT | PFAINT | 1.2.40.0.34.5.11 | 2‑S | 402 | Einzelfaktoranalysen | 1.2.40.0.34.5.11 | 3‑L | HMWKA | HMWK Aktivität | 1.2.40.0.34.5.11 | 3‑L | PKA | Präkallikrein Akt. | 1.2.40.0.34.5.11 | 3‑L | VWGPI | vWF Aktiv. (GPIb-R) | 1.2.40.0.34.5.11 | 3‑L | ADAA | ADAMTS 13 Aktivität | 1.2.40.0.34.5.11 | 2‑S | 403 | Thrombophilie Tests | 1.2.40.0.34.5.11 | 3‑L | PTTL2 | aPTT Lupus-s. 1+2 NP | 1.2.40.0.34.5.11 | 3‑L | LABPQ | LA-Bestät. aPTT ql. | 1.2.40.0.34.5.11 | 3‑L | dRVV2 | dRVVT 1+2 NP | 1.2.40.0.34.5.11 | 3‑L | LBDR1 | LA Bst.dRVVT-R.1+1NP | 1.2.40.0.34.5.11 | 3‑L | LBDR2 | LA Bst.dRVVT-R.1+2NP | 1.2.40.0.34.5.11 | 3‑L | LABD2 | LA Best.dRVVT 1+2 NP | 1.2.40.0.34.5.11 | 3‑L | LABDQ | LA-Bestät. dRVVT ql. | 1.2.40.0.34.5.11 | 3‑L | LABDR | LA-Bestät. dRVVT-Rto | 1.2.40.0.34.5.11 | 3‑L | PSREG | Phosphatids.-AK IgG | 1.2.40.0.34.5.11 | 3‑L | PSREM | Phosphatids.-AK IgM | 1.2.40.0.34.5.11 | 3‑L | PCPWY | Protein C Pathw. | 1.2.40.0.34.5.11 | 3‑L | PCP5D | Prot.C Pwy(V-d.Pl.) | 1.2.40.0.34.5.11 | 3‑L | APCRZ | APC-Res. (Ger.Z.) | 1.2.40.0.34.5.11 | 3‑L | APCRQ | APC-Resistenz(qual.) | 1.2.40.0.34.5.11 | 3‑L | PA675 | PAI-1 Mut. 675 4G/5G | 1.2.40.0.34.5.11 | 3‑L | PA844 | PAI-1 Mut. 844A>G | 1.2.40.0.34.5.11 | 1‑S | 500 | Klinische Chemie | 1.2.40.0.34.5.11 | 2‑S | 501 | Entzündungsmarker | 1.2.40.0.34.5.11 | 2‑S | 502 | Niere/Elektrolyte | 1.2.40.0.34.5.11 | 3‑L | SAMP | SAMP | 1.2.40.0.34.5.11 | 3‑L | VL24U | VL24U | 1.2.40.0.34.5.11 | 3‑L | GFRCG | GFRCG | 1.2.40.0.34.5.11 | 3‑L | BUNVO | BUNVO | 1.2.40.0.34.5.11 | 3‑L | BUNNA | BUNNA | 1.2.40.0.34.5.11 | 3‑L | BUNRR | BUNRR | 1.2.40.0.34.5.11 | 2‑S | 503 | Kardiale Marker | 1.2.40.0.34.5.11 | 2‑S | 504 | Leber/Pankreas | 1.2.40.0.34.5.11 | 2‑S | 505 | Hämolysemarker | 1.2.40.0.34.5.11 | 2‑S | 506 | Eisenstoffwechsel | 1.2.40.0.34.5.11 | 2‑S | 507 | Glukosestoffwechsel | 1.2.40.0.34.5.11 | 2‑S | 508 | Fettstoffwechsel | 1.2.40.0.34.5.11 | 2‑S | 509 | Proteindiagnostik | 1.2.40.0.34.5.11 | 3‑L | MGRAR | MGRAR | 1.2.40.0.34.5.11 | 3‑L | LDLO | Oxidiertes LDL | 1.2.40.0.34.5.11 | 1‑S | 600 | Endokrinologie | 1.2.40.0.34.5.11 | 2‑S | 601 | Adrenocortikales System | 1.2.40.0.34.5.11 | 2‑S | 602 | Katecholamine | 1.2.40.0.34.5.11 | 2‑S | 603 | Schilddrüsendiagnostik | 1.2.40.0.34.5.11 | 2‑S | 604 | Geschlechtshormone | 1.2.40.0.34.5.11 | 2‑S | 605 | Glukosestoffwechsel | 1.2.40.0.34.5.11 | 2‑S | 606 | Endokrinologie | 1.2.40.0.34.5.11 | 1‑S | 700 | Vitamine | 1.2.40.0.34.5.11 | 2‑S | 701 | Vitamine | 1.2.40.0.34.5.11 | 3‑L | AVB12 | AVB12 | 1.2.40.0.34.5.11 | 1‑S | 800 | Tumormarker | 1.2.40.0.34.5.11 | 2‑S | 801 | Tumormarker | 1.2.40.0.34.5.11 | 1‑S | 900 | Toxikologie | 1.2.40.0.34.5.11 | 2‑S | 901 | HarnScreening | 1.2.40.0.34.5.11 | 2‑S | 902 | Blut | 1.2.40.0.34.5.11 | 1‑S | 1000 | TDM | 1.2.40.0.34.5.11 | 2‑S | 1001 | Antibiotika | 1.2.40.0.34.5.11 | 2‑S | 1002 | Virostatika | 1.2.40.0.34.5.11 | 2‑S | 1003 | Antiepileptika | 1.2.40.0.34.5.11 | 2‑S | 1004 | Kardiaka | 1.2.40.0.34.5.11 | 2‑S | 1005 | Immunsuppressiva | 1.2.40.0.34.5.11 | 2‑S | 1006 | Sonstige | 1.2.40.0.34.5.11 | 1‑S | 1100 | Virologie | 1.2.40.0.34.5.11 | 2‑S | 1101 | HIV | 1.2.40.0.34.5.11 | 2‑S | 1102 | Hepatitis A | 1.2.40.0.34.5.11 | 2‑S | 1103 | Hepatitis B | 1.2.40.0.34.5.11 | 2‑S | 1104 | Hepatitis C | 1.2.40.0.34.5.11 | 2‑S | 1105 | Komplementbindungsreaktion | 1.2.40.0.34.5.11 | 2‑S | 1106 | Immunoassays | 1.2.40.0.34.5.11 | 2‑S | 1107 | PCR-Diagnostik | 1.2.40.0.34.5.11 | 3‑L | EVPQX | Ent.v.-RNA qn/SM PCR | 1.2.40.0.34.5.11 | 3‑L | IAPQX | Inf.A-V-RNAqn/SM PCR | 1.2.40.0.34.5.11 | 3‑L | IBPQX | Inf.B-V-RNAqn/SM PCR | 1.2.40.0.34.5.11 | 3‑L | MPPQX | MPV-RNA qn. /SM PCR | 1.2.40.0.34.5.11 | 3‑L | P1PQX | PIV-1-RNA qn/SM PCR | 1.2.40.0.34.5.11 | 3‑L | P2PQX | PIV-2-RNA qn/SM PCR | 1.2.40.0.34.5.11 | 3‑L | P3PQX | PIV-3-RNA qn./SM PCR | 1.2.40.0.34.5.11 | 2‑S | 1108 | Schnelltests | 1.2.40.0.34.5.11 | 1‑S | 1200 | Bakteriologie | 1.2.40.0.34.5.11 | 2‑S | 1201 | Syphilis-Diagnostik | 1.2.40.0.34.5.11 | 2‑S | 1202 | STD | 1.2.40.0.34.5.11 | 2‑S | 1203 | Borrelienserologie | 1.2.40.0.34.5.11 | 2‑S | 1204 | Chl. Psitakii Diagnostik | 1.2.40.0.34.5.11 | 2‑S | 1205 | Schnelltests | 1.2.40.0.34.5.11 | 2‑S | 1206 | Tuberkulose Diagnostik | 1.2.40.0.34.5.11 | 3‑L | MTQPX | MTB-DNA qn. /SM PCR | 1.2.40.0.34.5.11 | 3‑L | MTBP$ | MTBP$ | 1.2.40.0.34.5.11 | 3‑L | MTBP+ | MTBP+ | 1.2.40.0.34.5.11 | 3‑L | MTBPM | MTBPM | 1.2.40.0.34.5.11 | 3‑L | MTBPR | MTBPR | 1.2.40.0.34.5.11 | 3‑L | MTBPU | MTBPU | 1.2.40.0.34.5.11 | 2‑S | 1207 | Mykoplasmen Diagnostik | 1.2.40.0.34.5.11 | 3‑L | MYPQX | Myc.pn.DNA qn/SM PCR | 1.2.40.0.34.5.11 | 2‑S | 1208 | Malariasuche | 1.2.40.0.34.5.11 | 3‑L | PLLDH | Plasmodien-LDH /B | 1.2.40.0.34.5.11 | 1‑S | 1300 | Autoantikörperdiagnostik | 1.2.40.0.34.5.11 | 2‑S | 1301 | Rheumatoide Arthritis-assoziierte Autoantikörper | 1.2.40.0.34.5.11 | 3‑L | CCPAK | CCP-AK | 1.2.40.0.34.5.11 | 3‑L | MCVAK | MCV-AK | 1.2.40.0.34.5.11 | 2‑S | 1302 | Kollagenose-assoziierte Autoantikörper | 1.2.40.0.34.5.11 | 3‑L | CHRTF | ANA chromosom. Ti.IF | 1.2.40.0.34.5.11 | 3‑L | NUKTF | ANA nukleolär Ti. IF | 1.2.40.0.34.5.11 | 3‑L | HOMTF | ANA homogen Titer IF | 1.2.40.0.34.5.11 | 3‑L | HOMTF | ANA homogen Titer IF | 1.2.40.0.34.5.11 | 3‑L | SPFTF | ANA speck.fein Ti.IF | 1.2.40.0.34.5.11 | 3‑L | SPATF | ANA speck.atyp.Ti.IF | 1.2.40.0.34.5.11 | 3‑L | NUKTF | ANA nukleolär Ti. IF | 1.2.40.0.34.5.11 | 3‑L | NDQF | ANA nucl. dot ql. IF | 1.2.40.0.34.5.11 | 3‑L | NDTF | ANA nucl. dot Ti. IF | 1.2.40.0.34.5.11 | 3‑L | MNDQF | ANA m.nucl.dot ql.IF | 1.2.40.0.34.5.11 | 3‑L | MNDTF | ANA m.nucl.dot Ti.IF | 1.2.40.0.34.5.11 | 3‑L | KMTTF | ANA Kernmatrix Ti.IF | 1.2.40.0.34.5.11 | 3‑L | SPIQF | ANA Spindel qual. IF | 1.2.40.0.34.5.11 | 3‑L | SPITF | ANA Spindel Titer IF | 1.2.40.0.34.5.11 | 3‑L | CSMTF | ANA centrosom. Ti.IF | 1.2.40.0.34.5.11 | 3‑L | PCAQF | PCNA-AK qual. IF | 1.2.40.0.34.5.11 | 3‑L | PCATF | PCNA-AK Titer IF | 1.2.40.0.34.5.11 | 3‑L | PRAQF | Kernporen-AK ql. IF | 1.2.40.0.34.5.11 | 3‑L | PRATF | Kernporen-AK T. IF | 1.2.40.0.34.5.11 | 3‑L | HP2FI | HEP2-Ze. IF Interpr. | 1.2.40.0.34.5.11 | 3‑L | NSMAK | Nukleosomen-AK | 1.2.40.0.34.5.11 | 3‑L | S52AK | SS-A/Ro-52-AK | 1.2.40.0.34.5.11 | 3‑L | S60AK | SS-A/Ro-60-AK | 1.2.40.0.34.5.11 | 3‑L | CNBAK | CENP-B-AK | 1.2.40.0.34.5.11 | 3‑L | S52AQ | SS-A/Ro-52-AK qual. | 1.2.40.0.34.5.11 | 3‑L | S60AQ | SS-A/Ro-60-AK qual. | 1.2.40.0.34.5.11 | 3‑L | RNPSQ | RNPSQ | 1.2.40.0.34.5.11 | 3‑L | U170Q | U1-snRNP-70-AK qual. | 1.2.40.0.34.5.11 | 3‑L | U170Q | U1-snRNP-70-AK qual. | 1.2.40.0.34.5.11 | 3‑L | U1RAQ | U1-snRNP-A-AK qual. | 1.2.40.0.34.5.11 | 3‑L | U1RGQ | U1-snRNP-AK ql. | 1.2.40.0.34.5.11 | 3‑L | U1RGQ | U1-snRNP-AK ql. | 1.2.40.0.34.5.11 | 3‑L | U1RCQ | U1-snRNP-C-AK qual. | 1.2.40.0.34.5.11 | 3‑L | SMBAQ | SmB-AK qual. | 1.2.40.0.34.5.11 | 3‑L | SMDAQ | SmD-AK qual. | 1.2.40.0.34.5.11 | 3‑L | CNBAQ | CENP-B-AK qual. | 1.2.40.0.34.5.11 | 3‑L | GOAQF | Golgi-AK qual. IF | 1.2.40.0.34.5.11 | 3‑L | GOATF | Golgi-AK Titer IF | 1.2.40.0.34.5.11 | 3‑L | LYATF | Lysosomen-AK Ti. IF | 1.2.40.0.34.5.11 | 3‑L | RIBQF | Ribosomale-AK ql. IF | 1.2.40.0.34.5.11 | 3‑L | RPAQF | RNA-Polym.-AK ql. IF | 1.2.40.0.34.5.11 | 3‑L | RPATF | RNA-Polym.-AK Ti. IF | 1.2.40.0.34.5.11 | 3‑L | PMSQF | PM-Scl-AK qual. IF | 1.2.40.0.34.5.11 | 3‑L | PMSTF | PM-Scl-AK Titer IF | 1.2.40.0.34.5.11 | 3‑L | VMATF | Vimentin-AK Titer IF | 1.2.40.0.34.5.11 | 3‑L | VNATF | Vinkulin-AK Titer IF | 1.2.40.0.34.5.11 | 3‑L | P7AQF | PL-7/PL-12-AK ql. IF | 1.2.40.0.34.5.11 | 3‑L | P7ATF | PL-7/PL-12-AK Ti. IF | 1.2.40.0.34.5.11 | 3‑L | SRATF | SRP-AK Titer IF | 1.2.40.0.34.5.11 | 3‑L | SRPAK | SRP-AK | 1.2.40.0.34.5.11 | 2‑S | 1303 | Lebererkrankungen-assoziierte Autoantikörper | 1.2.40.0.34.5.11 | 3‑L | LKAQF | LKM-AK qual. IF | 1.2.40.0.34.5.11 | 3‑L | SMAFI | SMA(ASMA)IF Interpr. | 1.2.40.0.34.5.11 | 3‑L | SMAI | SMA(ASMA) Interpret. | 1.2.40.0.34.5.11 | 3‑L | AKAQF | Aktin-AK qual. IF | 1.2.40.0.34.5.11 | 3‑L | AKATF | Aktin-AK Titer IF | 1.2.40.0.34.5.11 | 3‑L | AMM4 | AMA-M4 | 1.2.40.0.34.5.11 | 3‑L | AMM9 | AMA-M9 | 1.2.40.0.34.5.11 | 3‑L | SLAAQ | SLA/LP-AK qual. | 1.2.40.0.34.5.11 | 3‑L | FAKTA | F-Aktin-AK | 1.2.40.0.34.5.11 | 3‑L | FAKAQ | F-Aktin-AK qual. | 1.2.40.0.34.5.11 | 3‑L | GP2AQ | GP210-AK qual. | 1.2.40.0.34.5.11 | 2‑S | 1304 | Perniziöse Anämie assoziierte Autoantikörper | 1.2.40.0.34.5.11 | 2‑S | 1305 | Vasculitis-assoziierte Antikörper | 1.2.40.0.34.5.11 | 3‑L | XANQF | x-ANCA(atyp.p) ql.IF | 1.2.40.0.34.5.11 | 3‑L | AANTF | Atyp. ANCA Ti.IF | 1.2.40.0.34.5.11 | 3‑L | PR3AC | PR3-AK cELISA | 1.2.40.0.34.5.11 | 3‑L | MPOC | MPO-AK cELISA | 1.2.40.0.34.5.11 | 3‑L | ELAAQ | Elastase-AK qual. | 1.2.40.0.34.5.11 | 3‑L | CATAQ | Cathepsin-AK qual. | 1.2.40.0.34.5.11 | 3‑L | LYSAQ | Lysozym-AK qual. | 1.2.40.0.34.5.11 | 3‑L | LACAQ | Lactoferrin-AK qual. | 1.2.40.0.34.5.11 | 3‑L | BPIAQ | BPI-AK qual. | 1.2.40.0.34.5.11 | 2‑S | 1306 | Goodpasture Syndrom assoziierte Autoantikörper | 1.2.40.0.34.5.11 | 2‑S | 1307 | IBD assoziierte Autoantikörper | 1.2.40.0.34.5.11 | 3‑L | ASCAQ | ASCA qual. | 1.2.40.0.34.5.11 | 3‑L | TTAGQ | tTGA IgG qual. | 1.2.40.0.34.5.11 | 3‑L | TTGAQ | tTGA qual. | 1.2.40.0.34.5.11 | 2‑S | 1308 | Diabetes Mellitus assoziierte Autoantikörper | 1.2.40.0.34.5.11 | 2‑S | 1309 | Paraneoplasie assoziierte Autoantikörper | 1.2.40.0.34.5.11 | 3‑L | KIAQ | Ki-AK qual. | 1.2.40.0.34.5.11 | 2‑S | 1310 | Sonstige Autoantikörper | 1.2.40.0.34.5.11 | 3‑L | SPDTF | Speicheldr.-AK Ti.IF | 1.2.40.0.34.5.11 | 3‑L | SRAQF | SRP-AK qual. IF | 1.2.40.0.34.5.11 | 1‑S | 1400 | Harndiagnostik | 1.2.40.0.34.5.11 | 2‑S | 1401 | Harnstreifen | 1.2.40.0.34.5.11 | 3‑L | ERYSU | ERYSU | 1.2.40.0.34.5.11 | 2‑S | 1402 | Harnsediment | 1.2.40.0.34.5.11 | 3‑L | G1ERV | G1-Erythrozyt.rl./US | 1.2.40.0.34.5.11 | 3‑L | GLERV | Glomerul.Ery.rel./US | 1.2.40.0.34.5.11 | 3‑L | PILZV | Pilze /US | 1.2.40.0.34.5.11 | 3‑L | RUEPV | Rundepithelien /US | 1.2.40.0.34.5.11 | 3‑L | PSZLV | Pseudozylinder /US | 1.2.40.0.34.5.11 | 3‑L | ZGLMU | Ziegelmehlsedim. /U | 1.2.40.0.34.5.11 | 2‑S | 1403 | Harnchemie | 1.2.40.0.34.5.11 | 3‑L | MGU | MGU | 1.2.40.0.34.5.11 | 3‑L | B1GRU | B1GRU | 1.2.40.0.34.5.11 | 3‑L | B2GRU | B2GRU | 1.2.40.0.34.5.11 | 3‑L | B1GLU | B1GLU | 1.2.40.0.34.5.11 | 3‑L | B2GLU | B2GLU | 1.2.40.0.34.5.11 | 3‑L | FLAMU | FLAMU | 1.2.40.0.34.5.11 | 2‑S | 1404 | Katecholamine | 1.2.40.0.34.5.11 | 2‑S | 1405 | Kortikoide | 1.2.40.0.34.5.11 | 1‑S | 1500 | Stuhldiagnostik | 1.2.40.0.34.5.11 | 2‑S | 1501 | Stuhldiagnostik | 1.2.40.0.34.5.11 | 1‑S | 1600 | Liquordiagnostik | 1.2.40.0.34.5.11 | 2‑S | 1601 | Liquordiagnostik | 1.2.40.0.34.5.11 | 3‑L | MNZRL | MNZRL | 1.2.40.0.34.5.11 | 3‑L | NEURL | NEURL | 1.2.40.0.34.5.11 | 3‑L | FKAPL | FKAPL | 1.2.40.0.34.5.11 | 3‑L | FLAML | FLAML | 1.2.40.0.34.5.11 | 3‑L | FKAPI | FKAPI | 1.2.40.0.34.5.11 | 1‑S | 1700 | Sondermaterialien | 1.2.40.0.34.5.11 | 2‑S | 1701 | Sondermaterialien | 1.2.40.0.34.5.11 | 3‑L | THRX | THRX | 1.2.40.0.34.5.11 | 3‑L | ERYX | ERYX | 1.2.40.0.34.5.11 | 3‑L | HBX | HBX | 1.2.40.0.34.5.11 | 3‑L | HKTX | HKTX | 1.2.40.0.34.5.11 | 3‑L | NEUAX | NEUAX | 1.2.40.0.34.5.11 | 3‑L | EOSAX | EOSAX | 1.2.40.0.34.5.11 | 3‑L | BASAX | BASAX | 1.2.40.0.34.5.11 | 3‑L | LYMAX | LYMAX | 1.2.40.0.34.5.11 | 3‑L | MONAX | MONAX | 1.2.40.0.34.5.11 | 3‑L | IMGAX | IMGAX | 1.2.40.0.34.5.11 | 3‑L | EOSRX | EOSRX | 1.2.40.0.34.5.11 | 3‑L | BASRX | BASRX | 1.2.40.0.34.5.11 | 3‑L | IMGRX | IMGRX | 1.2.40.0.34.5.11 | 3‑L | B1GRX | B1GRX | 1.2.40.0.34.5.11 | 3‑L | B2GRX | B2GRX | 1.2.40.0.34.5.11 | 3‑L | B1GX | B1GX | 1.2.40.0.34.5.11 | 3‑L | B2GX | B2GX | 1.2.40.0.34.5.11 | 3‑L | FERRX | FERRX | 1.2.40.0.34.5.11 | 2‑S | 1702 | Peritonealdialysat | 1.2.40.0.34.5.11 | 3‑L | THRY | THRY | 1.2.40.0.34.5.11 | 3‑L | ERYY | ERYY | 1.2.40.0.34.5.11 | 3‑L | HBY | HBY | 1.2.40.0.34.5.11 | 3‑L | HKTY | HKTY | 1.2.40.0.34.5.11 | 3‑L | NEURY | NEURY | 1.2.40.0.34.5.11 | 3‑L | EOSRY | EOSRY | 1.2.40.0.34.5.11 | 3‑L | BASRY | BASRY | 1.2.40.0.34.5.11 | 3‑L | LYMRY | LYMRY | 1.2.40.0.34.5.11 | 3‑L | MONRY | MONRY | 1.2.40.0.34.5.11 | 3‑L | TPY | TPY | 1.2.40.0.34.5.11 | 3‑L | ALBY | ALBY | 1.2.40.0.34.5.11 | 3‑L | CHOLY | CHOLY | 1.2.40.0.34.5.11 | 3‑L | TRIGY | TRIGY | 1.2.40.0.34.5.11 | 1‑S | 1800 | Allergiediagnostik/Globalmarker | 1.2.40.0.34.5.11 | 2‑S | 1801 | Allergiediagnostik/Globalmarker | 1.2.40.0.34.5.11 | 3‑L | DAO | DAO | 1.2.40.0.34.5.11 | 1‑S | 1900 | Allergiediagnostik Spez. IGE | 1.2.40.0.34.5.11 | 2‑S | 1901 | Gräserpollen RAST Klassen | 1.2.40.0.34.5.11 | 2‑S | 1902 | Baumpollen RAST Klassen | 1.2.40.0.34.5.11 | 2‑S | 1903 | Kräuterpollen RAST Klassen | 1.2.40.0.34.5.11 | 2‑S | 1904 | Milben RAST Klassen | 1.2.40.0.34.5.11 | 2‑S | 1905 | Epidermale Tierallergene RAST Klassen | 1.2.40.0.34.5.11 | 2‑S | 1906 | Mikroorganismen RAST Klassen | 1.2.40.0.34.5.11 | 2‑S | 1907 | Nahrungsmittel RAST Klassen | 1.2.40.0.34.5.11 | 2‑S | 1908 | Insektengifte RAST Klassen | 1.2.40.0.34.5.11 | 2‑S | 1909 | Berufliche Allergene RAST Klassen | 1.2.40.0.34.5.11 | 2‑S | 1910 | Diverse Allergene RAST Klassen | 1.2.40.0.34.5.11 | 2‑S | 1911 | Medikamente RAST Klassen | 1.2.40.0.34.5.11 | 2‑S | 1912 | Gräserpollen IGE quant. | 1.2.40.0.34.5.11 | 2‑S | 1913 | Baumpollen IGE quant. | 1.2.40.0.34.5.11 | 2‑S | 1914 | Kräuterpollen IGE quant. | 1.2.40.0.34.5.11 | 2‑S | 1915 | Milben IGE quant. | 1.2.40.0.34.5.11 | 2‑S | 1916 | Epidermale Tierallergene IGE quant. | 1.2.40.0.34.5.11 | 2‑S | 1917 | Mikroorganismen IGE quant. | 1.2.40.0.34.5.11 | 2‑S | 1918 | Nahrungsmittel IGE quant. | 1.2.40.0.34.5.11 | 2‑S | 1919 | Insektengifte IGE quant. | 1.2.40.0.34.5.11 | 2‑S | 1920 | Berufliche Allergene IGE quant. | 1.2.40.0.34.5.11 | 2‑S | 1921 | Diverse Allergene IGE quant. | 1.2.40.0.34.5.11 | 2‑S | 1922 | Medikamente IGE quant. | 1.2.40.0.34.5.11 |
|
|
Legende: Typ L=leaf, S=specializable, A=abstract, D=deprecated. NullFlavor OTH (other) schlägt Text in originalText vor. HL7 V3: NullFlavors werden im @nullFlavor Attribut statt in @code angegeben. |